Clinical Trials · NCT04725240
Open-Label Study of Setmelanotide in Hypothalamic Obesity
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Rhythm Pharmaceuticals, Inc.
- Enrollment
- 18
- Start date
- Jun 2021
- Locations
- 5 sites, United States
- Primary endpoint
- Percentage of Participants With ≥ 5% Reduction in BMI From Baseline After 16 Weeks of Setmelanotide Treatment